Acadian Asset Management’s Cabaletta Bio CABA Stock Holding History

Acadian Asset Management’s Portfolio CABA Stock Details CABA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-186,521	Closed	-$433K	–	1965
2025 Q3	$433K	Buy	186,521 +171,380	+1,132%	+$294K	﹤0.01%	1257
2025 Q2	$23K	Sell	15,141 -667,529	-98%	-$1.04M	﹤0.01%	1572
2025 Q1	$942K	Buy	682,670 +182,406	+36%	+$389K	﹤0.01%	948
2024 Q4	$1.13M	Buy	500,264 +242,843	+94%	+$853K	﹤0.01%	904
2024 Q3	$1.21M	Buy	+257,421	New	+$1.49M	﹤0.01%	873
2022 Q4	–	Sell	-147,480	Closed	-$95K	–	1782
2022 Q3	$95K	Hold	147,480	–	–	﹤0.01%	1376
2022 Q2	$157K	Hold	147,480	–	–	﹤0.01%	1257
2022 Q1	$298K	Buy	+147,480	New	+$386K	﹤0.01%	1119

Other funds holding CABA

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Superstring Capital Management New York $140M AUM 323.19% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Acadian Asset Management's CABA Position: Q4 2025 in Review

Acadian Asset Management sold out of Cabaletta Bio (CABA) in Q4 2025, closing a stake of 186,521 shares — an estimated $433K sold.

Acadian Asset Management first reported a position in CABA in Q1 2022 and held it in 8 quarters. The position peaked at $1.21M in Q3 2024. 95 funds tracked by Wall St. Rank hold CABA as of Q4 2025.

Acadian Asset Management reported no remaining Cabaletta Bio position as of Q4 2025 after selling out during the quarter.
Acadian Asset Management sold 186,521 Cabaletta Bio shares in Q4 2025, an estimated $433K.
Acadian Asset Management first reported a position in Cabaletta Bio in Q1 2022 and held it in 8 quarters.
Acadian Asset Management's Cabaletta Bio position peaked at $1.21M in Q3 2024.
95 funds tracked by Wall St. Rank held Cabaletta Bio as of Q4 2025.

Based on Acadian Asset Management's 13F filing for Q4 2025, filed 10 Feb 2026.